Burning Rock Biotech Limited
BNR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $516 | $537 | $563 | $508 |
| % Growth | -4% | -4.6% | 10.9% | – |
| Cost of Goods Sold | $153 | $174 | $183 | $144 |
| Gross Profit | $362 | $363 | $380 | $364 |
| % Margin | 70.3% | 67.6% | 67.5% | 71.7% |
| R&D Expenses | $232 | $347 | $422 | $368 |
| G&A Expenses | $262 | $438 | $568 | $490 |
| SG&A Expenses | $453 | $686 | $939 | $793 |
| Sales & Mktg Exp. | $191 | $248 | $370 | $303 |
| Other Operating Expenses | $35 | $0 | $0 | $0 |
| Operating Expenses | $720 | $1,033 | $1,360 | $1,161 |
| Operating Income | -$358 | -$669 | -$980 | -$797 |
| % Margin | -69.3% | -124.5% | -174.1% | -156.9% |
| Other Income/Exp. Net | $17 | $18 | $11 | $1 |
| Pre-Tax Income | -$341 | -$651 | -$969 | -$796 |
| Tax Expense | $6 | $2 | $2 | $1 |
| Net Income | -$347 | -$654 | -$971 | -$797 |
| % Margin | -67.2% | -121.6% | -172.4% | -156.9% |
| EPS | -33.67 | -63.84 | -93.47 | -76.45 |
| % Growth | 47.3% | 31.7% | -22.3% | – |
| EPS Diluted | -33.67 | -63.84 | -93.47 | -76.45 |
| Weighted Avg Shares Out | 10 | 10 | 10 | 10 |
| Weighted Avg Shares Out Dil | 10 | 10 | 10 | 10 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12 | $18 | $9 | $3 |
| Interest Expense | $0 | $0 | $0 | $2 |
| Depreciation & Amortization | $52 | $133 | $124 | $48 |
| EBITDA | -$270 | -$518 | -$856 | -$746 |
| % Margin | -52.4% | -96.4% | -152% | -147% |